Luis Teruel

Dr. Luis Teruel

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
JGJosep Gomez‐Lara
Josep Gomez‐Lara
MGMontserrat Gracida
Montserrat Gracida
FRFERNANDO RIVERO
FERNANDO RIVERO
AGAlejandro Gutiérrez‐Barrios
Alejandro Gutiérrez‐Barrios
GMGuillem Muntané‐Carol
Guillem Muntané‐Carol
Joan Antoni Gómez-HospitalJoan Antoni Gómez-Hospital
Joan Antoni Gómez-Hospital
Background: ST‐segment–elevation myocardial infarction complicated with no reflow after primary percutaneous coronary intervention is associated with adverse outcomes. Although several hyperemic drugs have been shown to improve the Thrombolysis in Myocardial Infarction flow, optimal treatment of no reflow remains unsettled. Saline infusion at 20 mL/min via a dedicated microcatheter causes (flow‐mediated) hyperemia. The objective is to compare the efficacy of pharmacologic versus flow‐mediated hyperemia in patients with ST‐segment–elevation myocardial infarction complicated with no reflow. Methods and Results: In the RAIN‐FLOW (Treatment of Slow‐Flow After Primary Percutaneous Coronary Intervention With Flow‐Mediated Hyperemia) study, 67 patients with ST‐segment–elevation myocardial infarction and no reflow were randomized to receive either pharmacologic‐mediated hyperemia with intracoronary adenosine or nitroprusside (n=30) versus flow‐mediated hyperemia (n=37). The angiographic corrected Thrombolysis in Myocardial Infarction frame count and the minimal microcirculatory resistance, as assessed with intracoronary pressure‐thermistor wire, dedicated microcatheter, and thermodilution techniques, were compared after study interventions. Both Thrombolysis in Myocardial Infarction frame count(40.2±23.1 versus 39.2±20.7; P =0.858) and minimal microcirculatory resistance (753.6±661.5 versus 993.3±740.8 Wood units; P =0.174) were similar between groups. Thrombolysis in Myocardial Infarction 3 flow was observed in 26.7% versus 27.0% ( P =0.899). Flow‐mediated hyperemia showed 2 different thermodilution patterns during saline infusion indicative of the severity of the no reflow phenomenon. In‐hospital death and nonfatal heart failure were observed in 10.4% and 26.9%, respectively. Conclusions: Both treatments showed similar (and limited) efficacy restoring coronary flow. Flow‐mediated hyperemia with thermodilution pattern assessment allowed the simultaneous characterization of the no reflow degree and response to hyperemia. No reflow was associated with a high rate of adverse outcomes. Further research is warranted to prevent and to treat no reflow in patients with ST‐segment–elevation myocardial infarction. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04685941.

7 January 2026 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
RTR Torres-Iglesias
R Torres-Iglesias
LTLuis Teruel
Luis Teruel
MSMa Sánchez-Corral
Ma Sánchez-Corral
PSPau Cerdà Serra
Pau Cerdà Serra
BVB Villanueva
B Villanueva
ARAntoni Riera-Mestre
Antoni Riera-Mestre

17 November 2020 in Circulation
Verified
Journal Article
Closed access
JAJuan Jose Rodriguez Arias
Juan Jose Rodriguez Arias
JGJosep Gomez-Lara
Josep Gomez-Lara
JCJuan Caballero-Borrego
Juan Caballero-Borrego
LOLuis Ortega-Paz
Luis Ortega-Paz
LTLuis Teruel
Luis Teruel
SBSalvatore Brugaletta
Salvatore Brugaletta
Background: Coronary vascular function of a chronic coronary total occlusion (CTO) immediately after recanalization is known to be poor and to be partially improved by pre-treatment with loading dose of ticagrelor vs. clopidogrel. It is unknown if this vascular dysfunction is maintained at long-term follow-up and may be improved by 1-year dual antiplatelet therapy (DAPT) with ticagrelor vs. clopidogrel. Methods: The TIGER is a prospective, open-label, two parallel-group controlled clinical trial, which 1:1 randomized 50 CTO patients to pre-PCI loading dose and subsequent 1-year DAPT with ticagrelor vs. clopidogrel. Coronary blood flow (CBF) under stepwise adenosine infusion was assessed after drug loading dose and at follow-up and compared between the two drug groups, adjusting for time of follow-up. Results: Out of 50 patients with index CBF evaluation, 38 (76%) patients underwent angiographic follow-up (23 and 15 at 1 and 3-year, respectively). A higher CBF area under the curve (AUC), already observed after loading dose in ticagrelor vs. clopidogrel group (p=0.027), was maintained at follow-up (AUC 34815.22±24206.06 vs. AUC 22712.47±13768.95; p=0.071). Specifically, whereas high ticagrelor loading dose-related CBF was sustained at follow-up (p=0.933), clopidogrel loading dose-related CBF increased at follow-up (p=0.039). Conclusion: The TIGER trial showed that DAPT with ticagrelor may maintain a higher CBF in a recanalized CTO as compared to clopidogrel, whose treated patients exhibit a lower CBF immediately after PCI with slight increase at follow-up. The clinical value of such sustained higher coronary flow should be evaluated in a larger group of patients. Download figure

15 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JMJuan Ignacio Mayol
Juan Ignacio Mayol
GMGuillem Muntané-Carol
Guillem Muntané-Carol
MGMontserrat Gracida
Montserrat Gracida
ARAndrea Ruberti
Andrea Ruberti
AMAna Marcano
Ana Marcano
Joan Antoni Gómez-HospitalJoan Antoni Gómez-Hospital
Joan Antoni Gómez-Hospital
Transcatheter aortic valve implantation (TAVI) has become the preferred treatment for patients with symptomatic severe aortic valve stenosis. Newer-generation devices, increased operator experience, and improved patient selection have contributed to a reduction in complication rates. However, the occurrence of new-onset left bundle branch block (LBBB) after TAVI remains high, and currently it is the most common complication associated with the procedure. This review discusses the current understanding of new-onset LBBB, including its causes, incidence, clinical outcomes, and management strategies.